Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivol...
Main Authors: | Lukas Šalaševičius, Goda Elizabeta Vaitkevičienė, Ramunė Pasaulienė, Rosita Kiudelienė, Ernesta Ivanauskaitė-Didžiokienė, Donatas Vajauskas, Nemira Jurkienė, Jelena Rascon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1010-660X/56/4/155 |
Similar Items
-
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01) -
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01) -
Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01) -
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
by: Bond DA, et al.
Published: (2017-05-01) -
Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report
by: Chulmin Park, et al.
Published: (2023-03-01)